Multiple Myeloma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-MM |
|---|---|
| Type | Disease |
| Aliases | MMPlasma cell myelomaМножинна мієломаМієломна хворобаХвороба Рустицького-Калера |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EHA-WORKUP-2024 SRC-NCCN-MM-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9732/3 |
|---|---|
| icd_o_3_topography | ["C42.1"] |
| icd_10 | C90.0 |
| who_classification | Plasma cell neoplasms — Plasma cell myeloma (multiple myeloma) |
Notes
Risk-stratified archetype — treatment intensity (triplet vs quadruplet, transplant vs no transplant) is shaped by R-ISS stage, cytogenetic risk category, and transplant eligibility. Second disease end-to-end after HCV-MZL; validates that the schema generalizes beyond etiologically_driven archetype (REFERENCE_CASE_SPECIFICATION §7.1 milestone M6).
Used By
Actionability
BMA-BRAF-V600E-MM- BRAF V600E is found in ~4% of multiple myeloma at diagnosis (more in extramedullary / pla...BMA-CCND1-IHC-MM- CCND1 (cyclin D1) overexpression in MM strongly correlates with t(11;14) and BCL2 depende...BMA-CCND1-T1114-MM- t(11;14) myeloma (~15-20%) — distinct biology with high BCL2/MCL1 ratio. Venetoclax monot...BMA-FGFR3-MUTATION-MM- In multiple myeloma, t(4;14) translocation places MMSET/FGFR3 under IgH control; ~30% of...BMA-KRAS-G12C-MM- KRAS G12C in myeloma — rare; tissue-agnostic G12Ci (sotorasib/adagrasib) not approved in...BMA-TP53-MUT-MM- TP53-mut / del(17p) myeloma — high-risk cytogenetics composite; quadruplet (D-VRd; PERSEU...BMA-TP53-R175H-MM- TP53 hotspot mutation in MM — high-risk genetic feature; quadruplet (D-VRd) preferred; CA...BMA-TP53-R248Q-MM- TP53 hotspot mutation in MM — high-risk genetic feature; quadruplet (D-VRd) preferred; CA...BMA-TP53-R273H-MM- TP53 hotspot mutation in MM — high-risk genetic feature; quadruplet (D-VRd) preferred; CA...BMA-TP53-R282W-MM- TP53 hotspot mutation in MM — high-risk genetic feature; quadruplet (D-VRd) preferred; CA...
Algorithms
ALGO-MM-1L- ALGO-MM-1LALGO-MM-2L- ALGO-MM-2LALGO-MM-3L- ALGO-MM-3L
Disease
DIS-KAPOSI- Kaposi sarcoma
Handbook Chapters
HB-MM-1L- Multiple myeloma: first-line risk and fitness reasoning
Indication
IND-MM-1L-DARA-RD- IND-MM-1L-DARA-RDIND-MM-1L-DVRD- IND-MM-1L-DVRDIND-MM-1L-RD- IND-MM-1L-RDIND-MM-1L-VRD- IND-MM-1L-VRDIND-MM-2L-DKD- IND-MM-2L-DKDIND-MM-3L-ISA-KD- IND-MM-3L-ISA-KDIND-MM-4L-CILTACEL-CART- IND-MM-4L-CILTACEL-CARTIND-MM-4L-TECLISTAMAB- IND-MM-4L-TECLISTAMABIND-MM-ELDERLY-FRAIL-VRD-LIGHT- IND-MM-ELDERLY-FRAIL-VRD-LIGHTIND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCE- IND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCEIND-MM-RR-2L-CILTACEL- IND-MM-RR-2L-CILTACELIND-MM-RR-3L-CILTACEL- IND-MM-RR-3L-CILTACELIND-MM-RR-3L-ELRANATAMAB- IND-MM-RR-3L-ELRANATAMABIND-MM-RR-3L-IDECEL- IND-MM-RR-3L-IDECELIND-MM-RR-3L-TALQUETAMAB- IND-MM-RR-3L-TALQUETAMABIND-MM-RR-3L-TECLISTAMAB- IND-MM-RR-3L-TECLISTAMAB
Procedures
SUR-ASCT-AUTOLOGOUS- Autologous stem cell transplantation (HDM/ASCT)
Questionnaires
QUEST-MM-1L- Multiple Myeloma — newly diagnosed (1L)
Red flag
RF-ISS-1- Multiple myeloma with ISS stage 1 — β2-microglobulin <3.5 mg/L AND albumin ≥3.5 g/dL — st...RF-ISS-3- Multiple myeloma with ISS stage 3 — β2-microglobulin ≥5.5 mg/L — high-risk presentation;...RF-MM-BCMA-EXPRESSION-POS- BCMA (B-cell maturation antigen, TNFRSF17) expression on plasma cells in relapsed/refract...RF-MM-CD38-EXPRESSION-DARA-CANDIDATE- CD38 expression on plasma cells in newly-diagnosed or relapsed/ refractory multiple myelo...RF-MM-CORD-COMPRESSION- Multiple myeloma with malignant epidural spinal cord compression: new motor deficit, sens...RF-MM-FRAILTY-AGE- Frailty profile precluding standard-dose VRd / D-VRd induction in MM: IMWG frailty score...RF-MM-HIGH-RISK-CYTOGENETICS- Multiple myeloma high-risk cytogenetics: any of t(4;14), t(14;16), t(14;20), del(17p)/TP5...RF-MM-HYPERCALCEMIA- Multiple myeloma with hypercalcemia (corrected serum calcium ≥11 mg/dL or symptomatic): p...RF-MM-HYPERVISCOSITY- Multiple myeloma with hyperviscosity syndrome — uncommon but classic in IgA-MM (M-spike >...RF-MM-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating MM induct...RF-MM-RENAL-DYSFUNCTION- Multiple myeloma with significant renal dysfunction: CrCl <60 mL/min or serum creatinine...RF-MM-T11-14-ACTIONABLE- t(11;14)(q13;q32) IGH/CCND1 translocation in multiple myeloma — ~15-20% prevalence, BCL-2...RF-MM-TRANSFORMATION-PROGRESSION- Aggressive plasma-cell biology indicating need for intensified MM induction: plasma cell...RF-R-ISS-3-HIGH-RISK- Multiple myeloma with R-ISS stage 3 — ISS-3 (β2M ≥5.5) PLUS LDH above ULN PLUS high-risk...
Sources
SRC-ALCYONE-MATEOS-2018- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaSRC-CARTITUDE-1-BERDEJA-2021- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor...SRC-CARTITUDE-4-SAN-MIGUEL-2023- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaSRC-CASTOR-PALUMBO-2016- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaSRC-EHA-EMN-MM-2025- EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with...SRC-ELOQUENT-3-DIMOPOULOS-2018- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple MyelomaSRC-ESMO-MM-2023- ESMO Clinical Practice Guideline on Multiple MyelomaSRC-FDA-ISATUXIMAB-2020- FDA approval of Sarclisa (isatuximab-irfc) for multiple myeloma — BLA 761113SRC-GRIFFIN-VOORHEES-2020- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly di...SRC-ICARIA-ATTAL-2019- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose...SRC-IKEMA-MOREAU-2021- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multic...SRC-IMROZ-FACON-2024- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaSRC-KARMMA-MUNSHI-2021- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaSRC-MAGNETISMM-3-LESOKHIN-2023- Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial ResultsSRC-MAIA-FACON-2019- Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaSRC-MAJESTEC-1-MOREAU-2022- Teclistamab in Relapsed or Refractory Multiple MyelomaSRC-MONUMENTAL-1-CHARI-2022- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple MyelomaSRC-PERSEUS-SONNEVELD-2024- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaSRC-POLLUX-DIMOPOULOS-2016- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaSRC-TOURMALINE-MM1-MOREAU-2016- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma